Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Jason Daly Sells 6,613 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 6,613 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $17.70, for a total transaction of $117,050.10. Following the sale, the executive vice president directly owned 245,171 shares in the company, valued at $4,339,526.70. The trade was a 2.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amneal Pharmaceuticals Trading Down 2.2%

Shares of Amneal Pharmaceuticals stock opened at $17.27 on Friday. The firm has a 50-day simple moving average of $17.15 and a two-hundred day simple moving average of $14.56. The company has a market cap of $5.51 billion, a P/E ratio of 35.24 and a beta of 1.27. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $9.15 and a fifty-two week high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Institutional Trading of Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Globeflex Capital L P purchased a new position in Amneal Pharmaceuticals during the 2nd quarter worth approximately $2,536,000. Bank of New York Mellon Corp acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter worth $17,573,000. Handelsbanken Fonder AB increased its stake in Amneal Pharmaceuticals by 3.0% in the second quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock valued at $1,322,000 after purchasing an additional 2,200 shares during the period. Bank of America Corp DE raised its holdings in shares of Amneal Pharmaceuticals by 50.0% in the first quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock valued at $8,413,000 after buying an additional 225,637 shares during the last quarter. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at about $4,165,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AMRX. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. UBS Group upped their price objective on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Barclays raised their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $17.67.

Key Headlines Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Amneal entered the second half of 2026 with higher guidance and a broader product pipeline, supporting the company’s growth outlook. However, erosion of its Rytary product remains a concern. Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
• Positive Sentiment: The Kashiv transaction gives Amneal an integrated biosimilars platform that could become a significant long-term growth engine, expanding its pipeline and commercial opportunities. Integration, regulatory execution and product adoption are key hurdles. Can Amneal’s Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
• Neutral Sentiment: Brokerages have a consensus price target of $17.67, indicating limited potential upside relative to recent trading levels and suggesting analysts see a fairly balanced risk-reward profile. Amneal Pharmaceuticals Receives $17.67 Consensus Price Target
• Neutral Sentiment: AMRX has rallied 44.8% over three months, but the advance now faces tests from upcoming earnings, new product launches and pipeline progress. Its higher valuation and Rytary revenue erosion could limit further gains. AMRX Stock Surges 44.8% in 3 Months
• Negative Sentiment: Amneal executives disclosed sizable stock sales. EVP Jason B. Daly sold 210,000 shares for approximately $3.65 million and an additional 6,613 shares, while EVP Nikita Shah sold 146,403 shares for approximately $2.56 million. The transactions substantially reduced their ownership stakes and may be weighing on investor sentiment, although insider sales do not necessarily indicate deteriorating fundamentals. Amneal Executive Stock Sale Filings

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.